Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics, Inc. (ATOS)
:ATOS
Top Page
Atossa Therapeutics
(NASDAQ:ATOS)
Rating:36Underperform
Price Target:―
Positive Factors
Clinical Trials
Positive topline data from the KARISMA-Endoxifen Phase 2 study demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density and was well tolerated.
Market Opportunity
The market potential of approximately a billion dollars presents high rewards for these risks.
Negative Factors
Clinical Trial Risks
There are high risks due to the long development road and potential for clinical trial failures.
Competitive Landscape
The oral SERD space in second-line and beyond patients has become increasingly competitive, though to date, Phase 3 trials have only indicated a benefit in ESR1 mutant patients.
Atossa Therapeutics (ATOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$108.75M
Dividend YieldN/A
Average Volume (3M)1.22M
Price to Earnings (P/E)―
Beta (1Y)2.02
Revenue GrowthN/A
EPS Growth15.09%
CountryUS
Employees15
SectorHealthcare
Sector Strength40
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding129,170,000
10 Day Avg. Volume661,188
30 Day Avg. Volume1,220,181
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)1.80
Price to Sales (P/S)0.00
P/FCF Ratio-5.28
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue1.47K
Enterprise Value/Gross Profit-13.26K
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$5.63Price Target Upside570.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Atossa Therapeutics Business Overview & Revenue Model
Company DescriptionAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
How the Company Makes MoneyAtossa Therapeutics primarily generates revenue through strategic partnerships and collaborations with other pharmaceutical companies, licensing agreements, and potential milestone payments related to the development and commercialization of its drug candidates. As a clinical-stage company, revenue is also contingent upon successful clinical trial results and subsequent regulatory approvals. Additionally, Atossa may engage in fundraising activities to support its ongoing research and development efforts.
Atossa Therapeutics Earnings Call Summary
Earnings Call Date:May 13, 2025
(Q4-2024)
| % Change Since: 0.00%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Positive
The earnings call presented a generally positive outlook with notable reductions in operating costs and promising clinical advancements for (Z)-endoxifen, particularly in metastatic breast cancer. However, the financial impact of a write-off and decreased interest income offset some of these positives.Q4-2024 Updates
Positive Updates
Reduced Operating Expenses
Total operating expenses for the year were $27.6 million, down from $31.4 million in 2023, a decrease of $3.8 million, reflecting disciplined spending in both R&D and G&A.
R&D Cost Reduction
R&D expenses declined by $3.2 million from $17.3 million in 2023 to $14.1 million in 2024, driven by a reduction in clinical and preclinical spending on (Z)-endoxifen trials and drug development.
Strong Cash Position
The company closed the year with $71.1 million in cash and cash equivalents, providing a healthy runway to advance (Z)-endoxifen and other research initiatives.
(Z)-endoxifen Clinical Progress
(Z)-endoxifen showed promising results in Phase I and Phase II studies, demonstrating robust plasma concentration, a 26% clinical benefit rate in difficult-to-treat settings, and significant reduction in mammographic breast density.
Metastatic Breast Cancer Focus
The company is prioritizing the advancement of (Z)-endoxifen in metastatic breast cancer, aiming for a potential expedited approval and faster time to market.
Negative Updates
Investment Write-off
A write-off of $1.7 million was recorded as Dynamic Cell Therapies ceased operations in the fourth quarter of 2024.
Decreased Interest Income
Interest income was $4.1 million for the year, a slight decrease compared to 2023 due to a lower average invested balance in 2024.
G&A Expense Details
Professional fees increased by $1.8 million year-over-year, primarily due to higher legal and investor relation costs, along with accounting fees tied to public company expenses.
Company Guidance
In their recent earnings call, Atossa Therapeutics provided guidance highlighting several key metrics. Operating expenses for 2024 decreased to $27.6 million, down from $31.4 million in 2023, due to disciplined spending in R&D and G&A. R&D expenses fell by $3.2 million to $14.1 million, driven by a $2.6 million reduction in spending on (Z)-endoxifen trials. G&A expenses decreased slightly to $13.5 million, with a $1.9 million reduction in compensation costs. The company reported a net loss of $25.5 million or $0.20 per share, compared to $30.1 million or $0.24 per share in the previous year. Atossa closed the year with $71.1 million in cash and cash equivalents, providing a strong financial position to advance their lead program, (Z)-endoxifen, particularly in metastatic breast cancer settings. Additionally, a Phase I study demonstrated a clinical benefit rate of approximately 26% in patients with previous progression on multiple therapies, and a related Phase II study suggested nearly a five-month improvement in progression-free survival for certain subgroups. The company plans to focus on the U.S. FDA process for a streamlined path to market, with further guidance expected as they engage with key opinion leaders and regulatory authorities.Atossa Therapeutics Financial Statement Overview
Summary
Atossa Therapeutics faces significant financial challenges, reflected in its inability to generate revenue and ongoing operational losses. While the company benefits from a debt-free balance sheet and strong equity, its cash flow situation is concerning, with negative cash flow metrics indicating reliance on external financing. The overall financial health is weak, necessitating strategic changes to improve revenue generation and operational efficiency.Income Statement
Atossa Therapeutics has consistently reported zero revenue over the years, with increasing net losses, reflecting challenges in achieving profitability. The TTM (Trailing-Twelve-Months) data shows a worsening net loss, indicating further financial strain. The absence of revenue growth and negative profit margins highlight significant operational challenges.10
Very Negative
Balance Sheet
The company maintains a strong equity position with no debt, which is a positive financial indicator. However, the consistent net losses and decreasing equity over time raise concerns about the sustainability of its financial position. The equity ratio remains high, suggesting financial stability despite operational losses.40
Negative
Cash Flow
Atossa Therapeutics exhibits negative operating and free cash flow, indicating cash burn due to ongoing operational expenses without revenue generation. The company relies on financing activities to support operations, which may not be sustainable in the long term without revenue growth. The cash flow ratios indicate inefficiency in converting cash flow into profits, raising concerns over liquidity.25
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -17.00K | -23.00K | -8.00K | -23.00K | -46.60K |
| EBITDA | -25.49M | -31.35M | -27.68M | -20.50M | -14.56M |
| Net Income | -25.50M | -30.09M | -26.23M | -20.61M | -21.10M |
Balance Sheet | |||||
| Total Assets | 76.44M | 96.25M | 123.53M | 141.26M | 42.84M |
| Cash, Cash Equivalents and Short-Term Investments | 71.08M | 88.46M | 110.89M | 136.38M | 39.55M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 18.05K |
| Total Liabilities | 4.97M | 5.24M | 5.57M | 3.13M | 15.67M |
| Stockholders Equity | 71.48M | 91.02M | 117.96M | 138.14M | 27.17M |
Cash Flow | |||||
| Free Cash Flow | -21.05M | -20.95K | -20.79M | -16.48M | -11.58M |
| Operating Cash Flow | -21.03M | -20.94K | -20.76M | -16.47M | -11.57M |
| Investing Cash Flow | -19.00K | -14.00 | -4.73M | -9.00K | -9.37K |
| Financing Cash Flow | 3.67M | -1.48K | 0.00 | 113.30M | 38.55M |
Atossa Therapeutics Technical Analysis
Neutral
0.84
Price Trends
0.86
Positive
0.79
Positive
0.97
Negative
Market Momentum
0.02
Negative
50.44
Neutral
46.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATOS, the sentiment is Neutral. The current price of 0.84 is below the 20-day moving average (MA) of 0.86, below the 50-day MA of 0.86, and below the 200-day MA of 0.97, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 50.44 is Neutral, neither overbought nor oversold. The STOCH value of 46.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ATOS.
Atossa Therapeutics Risk Analysis
Atossa Therapeutics disclosed 48 risk factors in its most recent earnings report. Atossa Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Atossa Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $7.34B | -0.07 | -63.86% | 2.34% | 16.17% | 0.23% | |
49 Neutral | $108.23M | ― | -61.14% | ― | -100.00% | -24.28% | |
47 Neutral | $51.38M | ― | -116.63% | ― | -100.00% | 24.59% | |
43 Neutral | $79.82M | ― | -62.34% | ― | ― | 86.65% | |
37 Underperform | $82.26M | ― | -63.22% | ― | -100.00% | -26.44% | |
36 Underperform | $108.75M | ― | -34.87% | ― | ― | 15.09% | |
35 Underperform | $106.30M | ― | -54.64% | ― | ― | 1.27% |
* Healthcare Sector Average
Performance Comparison
ATOS
Atossa Therapeutics
0.84
-0.50
-37.31%
ANIX
Anixa Biosciences
3.44
0.50
17.01%
PLRX
Pliant Therapeutics
1.43
-10.93
-88.43%
SNTI
Senti Biosciences
1.95
-0.49
-20.08%
ZURA
Zura Bio
1.91
-1.58
-45.27%
HLVX
HilleVax, Inc
2.06
0.29
16.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.